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Why now?
A national debate on cannabis has gathered momentum for several 
reasons. First, the introduction of a bill that focuses on the use of 
cannabis for medical purposes has raised issues about the access to 
and the efficacy of the psychoactive ingredients of the cannabis plant 
for the management of medical conditions. Second, there have been 
changes in the legal status of cannabis in several countries around 
the world, including Uruguay and the USA. Third, in South Africa 
(SA), the abuse of alcohol, tobacco, cannabis and other psychoactive 
substances or drugs continues to be a major problem, causing 
immense suffering to individuals, families and communities and 
costing the national economy severely.[1-3] 
Brief history
Cannabis is subject to several international and national conventions 
and laws. The International Drug Convention of 1961 agrees that 
states should not commercialise cannabis, but allows states to decide 
for themselves the extent to which laws and policies should focus on 
the different strategies of supply, demand and harm reduction. The 
Prevention of and Treatment for Substance Abuse Act 70 of 2008 
speaks to The National Drug Master Plan, which emphasises all 
three of these strategies for combating the abuse of alcohol, tobacco, 
cannabis and other psychoactive substances.
Reduction strategies
Supply reduction refers to policing efforts to curb the manufacture 
and distribution of alcohol, tobacco, cannabis and other psychoactive 
substances. Demand reduction refers to preventive efforts to decrease 
demand for such substances. Harm reduction refers to policies and 
interventions aimed at reducing the harmful consequences of alcohol, 
tobacco, cannabis and other psychoactive substance use. A focus on 
harm reduction does not intend to send a message to the community 
that risky behaviours and the use of psychoactive substances or drugs 
are acceptable. Rather, such policies are formulated based on the 
scientific evidence regarding what works to improve public health 
and reduce social harms when tobacco, alcohol, cannabis and other 
psychoactive substances are already being used.[4-6]
Harms of marijuana
Scientific research has established that cannabis is associated with 
a range of potential harms to individuals and to society. Data on 
smoking cannabis indicate that this practice is linked to cardio-
vascular and respiratory disorders, as well as to cognitive impairment 
and mental disorders.[7] Exposure to cannabis in adolescence, a time 
of significant neurodevelopment, is associated with a higher risk for 
psychotic disorders in later life. The risk is dose related.[8] Highly 
potent cannabis represents a significant public health problem. Acute 
cannabis use, for example, is associated with increased risk of motor 
vehicle collisions, including fatal crashes.[9] Cannabis use should 
therefore be prevented, and its continued use treated, using evidence-
based approaches.
Benefits of marijuana
Medications such as dronabinol and nabilone consist of psychoactive 
ingredients of the cannabis plant, and are available in a number of 
countries for the treatment of medical conditions, such as nausea 
after chemotherapy, pain and spasticity. There is ongoing interest in 
the use of psychoactive ingredients of the cannabis plant in various 
other medical contexts, including for weight gain in HIV-positive 
patients. However, there are relatively few rigorous data in this area, 
and little is known about safe dose limits.[10] In the SA setting, there 
is a need for greater health research in general, including work on 
cannabis. This needs to be balanced against national health research 
priorities, which have highlighted the importance of additional 
research on several aspects of mental health that are relevant to SA’s 
burden of disease, including mortality and morbidity.[11]
Recommendations 
• The National Drug Master Plan emphasises the importance of an 
integrated approach to supply reduction, demand reduction, and 
harm reduction strategies for combating alcohol, tobacco, cannabis 
and other psychoactive substance use and abuse in SA. For any 
particular substance, the balance between these three strategies, 
and the precise nature of the approach taken, should be evidence 
based. 
• An assessment of currently available data in other countries indi-
cates that alcohol is the substance that causes the most individual 
and societal harm,[12] and it is therefore key to put particular efforts 
into implementing the most evidence-based policies and interven-
tions for combating such harm. This would encompass addressing 
a range of upstream drivers of alcohol use, as well as prevention 
and intervention efforts.[13] 
• Efforts at harm reduction have been particularly poorly resourced 
in SA, and given the enormous profits made by the liquor industry 
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there is a need and obligation for this industry to be substantively 
more involved in evidence-based harm-reduction efforts.
• In terms of cannabis, local school survey data suggest high rates 
of experimentation during early adolescence;[14] hence, evidence-
based interventions that include a strong focus on harm reduction 
are also needed in this population, which comprises a large 
proportion of South Africans. 
• There are few data to indicate that supply reduction via 
criminalisation is effective in reducing cannabis abuse. At the same 
time there are insufficient data to indicate that the legalisation 
of cannabis will not be harmful. The immediate focus should 
therefore be decriminalisation rather than legalisation. 
• With regard to medical marijuana, products based on ingredients 
of the cannabis plant should undergo standard evaluation by the 
Medicines Control Council to assess their benefits and risks for the 
treatment of particular medical conditions.
• Evidence-based approaches that reduce harm from continued and 
chronic use of alcohol and cannabis (particularly among vulner-
able groups such as adolescents and people with mental disorders) 
deserve greater attention and additional resources.
• Mental, neurological, and substance use disorders contribute signifi-
cantly to SA’s burden of disease. Proportionally and quantitatively, 
more research attention and resources need to focus on this area.
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